Medivir publishes disclosure document regarding rights issue
Summary by AI BETAClose X
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.
Medivir AB (publ) (“Medivir” or the “Company”) (Nasdaq Stockholm: MVIR) publishes a disclosure document in connection with the Company’s new share issue with preferential rights for existing shareholders of approximately SEK 151 million, as resolved by the Board of Directors on 8 October 2025 and approved by the Extraordinary General Meeting held on 10 November 2025 (the “Rights Issue”). The Rights Issue may be increased by an over-allotment issue of up to SEK 20 million (the “Over-allotment Issue”) and is fully secured through subscription undertakings and guarantee commitments from existing shareholders and external investors. The disclosure document has been registered with the Swedish Financial Supervisory Authority and is available on the Company’s website.
Disclosure document
In connection with the Rights Issue and the Over-allotment Issue, the Company has prepared a disclosure document in accordance with Article 1.4 db and Article 1.5. ba of Regulation (EU) 2017/1129 of the European Parliament and of the Council on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the “Prospectus Regulation”). The disclosure document has been prepared in accordance with the requirements of Annex IX to the Prospectus Regulation.
Today, Medivir announces that the disclosure document has been registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on the Company’s website www.medivir.se and on DNB Carnegie’s website, www.dnbcarnegie.se.
Preliminary timetable for the Rights Issue
The below timetable for the Rights Issue is preliminary and may be adjusted.
| 14 November 2025 | Publication of disclosure document |
| 17 November – 27 November 2025 | Trading in subscription rights |
| 17 November – 2 December 2025 | Subscription period |
| 17 November – on or about 10 December 2025 | Trading in BTAs (paid subscribed shares) |
| 3 December 2025 | Expected announcement of the outcome of the Rights Issue |
Advisors
DNB Carnegie Investment Bank AB (publ) and Zonda Partners act as Joint Bookrunners. Advokatfirman Lindahl KB is legal adviser to the Company. DNB Carnegie Investment Bank AB (publ) also acts as issuing agent in connection with the Rights Issue.
Latest directors dealings
- 10 hours ago Savannah Energy
- 11 hours ago Buccaneer Energy PLC
- 11 hours ago Savannah Energy
- 11 hours ago Carclo
- 12 hours ago Schroder Japan Growth Fund